ENTRY       D10161                      Drug
NAME        Sarilumab (USAN);
            Sarilumab (genetical receombination) (JAN);
            Kevzara (TN)
PRODUCT     KEVZARA (sanofi-aventis U.S. LLC)
FORMULA     C6388H9918N1718O1998S44
EXACT_MASS  144073.5003
MOL_WEIGHT  144162.2723
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGRSLRL SCAASRFTFD DYAMHWVRQA PGKGLEWVSG ISWNSGRIGY
            ADSVKGRFTI SRDNAENSLF LQMNGLRAED TALYYCAKGR DSFDIWGQGT MVTVSSASTK
            GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
            LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF
            LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR
            VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVTYL PPSRDELTKN
            QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN
            VFSCSVMHEA LHNHYTQKSL SLSPGK
            (Light chain)
            DIQMTQSPSS VSASVGDRVT ITCRASQGIS SWLAWYQQKP GKAPKLLIYG ASSLESGVPS
            RFSGSGSGTD FTLTISSLQP EDFASYYCQQ ANSFPYTFGQ GTKLEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H143-H199, H219-L214, H225-H'225, H228-H'228, H260-H320, H366-H424, H'22-H'96, H'143-H'199, H'219-L'214, H'260-H'320, H'366-H'424, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
            Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
REMARK      Therapeutic category: 3999
            ATC code: L04AC14
            Product: D10161<JP/US>
EFFICACY    Anti-inflammatory, Antirheumatic, Anti-IL-6 receptor antibody
  DISEASE   Rheumatoid arthritis [DS:H00630]
  TYPE      Monoclonal antibody
TARGET      IL6R (CD126) [HSA:3570] [KO:K05055]
  PATHWAY   hsa04060(3570)  Cytokine-cytokine receptor interaction
            hsa04630(3570)  JAK-STAT signaling pathway
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC14 Sarilumab
                  D10161  Sarilumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Sarilumab
                 D10161  Sarilumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D10161  Sarilumab (USAN); Sarilumab (genetical receombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D10161  Sarilumab
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D10161  Sarilumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D10161  Sarilumab
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D10161  Sarilumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interleukin receptors
                IL6R (CD126)
                 D10161  Sarilumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10161
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10161
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10161
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10161
DBLINKS     CAS: 1189541-98-7
            PubChem: 135626879
///
